Tradestie Institutional Equity Comparison Engine

EKSO vs AACB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-08-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AACB Overall Edge

AACB Captures Institutional Edge (2โ€“1 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AACB (AACB) driven by superior Valuation, Growth & Margin while EKSO counters with relative strength in Momentum & Technical. Fundamentally, EKSO trades at N/M Forward P/E with -119.7% operating margin (-38.3% YoY revenue) versus AACB at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EKSO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AACB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AACB
EKSO N/M vs AACB N/M Fwd P/E
Growth & Margin Winner AACB
Op Margin -119.7% vs 0.0% ยท YoY -38.3% vs +0.0%
Momentum & Technical Winner EKSO
1Y +62.6% vs +5.5% ยท 52W Pos 87% vs 98%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
1M Return +25.53%
1Y Return +62.6%
Forward P/E N/M
Unified AI Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
AACB US Equity
AACB
Institutional Equity
$10.59
+0.09% 1D
Market Cap $292.8M
1M Return +0.86%
1Y Return +5.48%
Forward P/E N/M
Unified AI Score
55.3 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EKSO +62.6% AACB +5.48% Spread: +4113.81 pp (EKSO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EKSO TTM Op. Margin: -119.7% AACB TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs AACB. Trailing 12-month operating profitability (EKSO -119.7% vs AACB 0.0%) and valuation multiples (EKSO N/M vs AACB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EKSO (1) vs AACB (8)
Institutional Metric EKSO AACB Criterion Row Winner
Market Capitalization Scale $42.0M $292.8M Larger Scale AACB
Trailing P/E Ratio Valuation N/M 62.2x Lower Multiple AACB
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -38.3% +0.0% Higher Growth AACB
Operating Margin (TTM) Profitability -119.7% 0.0% Higher Margin AACB
Net Profit Margin Profitability -91.4% 0.0% Higher Margin AACB
Return on Equity (ROE) Capital Efficiency -107.6% 0.0% Higher ROE AACB
52-Week Range Position Momentum 87% ($0โ€“$14) 98% ($10โ€“$11) Stronger Trend AACB
Beta / 30D Volatility Risk Regime 2.16ฮฒ ยท 76% Vol 0.02ฮฒ ยท 3% Vol Lower Realized Risk AACB
Unified Institutional Score Composite Signal 58.1 / 100 (HOLD) 55.3 / 100 (HOLD) Higher Composite EKSO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EKSO vs AACB Buy Guide
EKSO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EKSO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AACB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EKSO nor AACB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.